GE HealthCare’s PET imaging agent gains Alzheimer’s label expansion
The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.
Diagnostics
Centenarians – unlocking the secrets of living to 100
Dementia Action Week 2024: the future of Alzheimer’s diagnostics
Drug delivery innovations push forth women’s health
Prothea debuts with $13m to develop cancer diagnostics and treatment
Q&A: BARDA wants to back tech that can combat multiple infections, says director
King Charles’ diagnosis raises awareness on prostate condition
Call for earlier diagnosis to improve Gaucher disease outcomes
